PSTV 8-K: Smart Summary
78% reductionPlus Therapeutics, Inc. discloses that on February 9, 2026, the Compensation Committee approved discretionary cash bonuses for Named Executive Officers for Fiscal Year 2025, and provides an updated Summary Compensation Table including those bonus amounts and total compensation figures.
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Executive Compensation
- Marc H. Hedrick, M.D. (President and CEO) — FY2025: base salary $585,000; option awards $3,531,841; restricted stock awards $1,100,647; non-equity incentive plan compensation (discretionary cash bonus) $305,663; all other compensation $43,581; total $5,566,732. FY2024: base salary $556,400; option awards $335,348; non-equity incentive plan compensation $321,321; all other compensation $47,216; total $1,260,285
- Andrew Sims (CFO) — FY2025: base salary $390,000; option awards $810,388; restricted stock awards $264,154; non-equity incentive plan compensation (discretionary cash bonus) $149,175; all other compensation $17,562; total $1,631,279. FY2024: base salary $372,750; option awards $74,758; non-equity incentive plan compensation $156,555; all other compensation $17,053; total $621,116
- Norman LaFrance, M.D. (Former CMO) — FY2025: all compensation categories $0; total $0. FY2024: base salary $258,446; all other compensation $27,466; total $285,912
Departures
- Former Chief Medical Officer Norman LaFrance, M.D. — stepped down from his position as Chief Medical Officer on June 11, 2024; received $0 in total compensation for Fiscal Year 2025
§ MORE SUMMARIES
More PSTV Smart Summaries
Other filings for PLUS THERAPEUTICS, INC. with a Smart Summary.
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
Enters $17.35M at-the-market equity offering agreement
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
Stockholders approve director election, auditor ratification, and stock plan
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
Q2 2026 earnings results
10-Q$PSTVPLUS THERAPEUTICS, INC.Smart Summary
10-Q Filing
NIH funds $3M trial for brain cancer radiotherapy
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
Regains Nasdaq compliance after reverse stock split
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
Q1 2026 earnings results
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
Annual meeting scheduled for May 14, stockholder proposal deadline moved
8-K$PSTVPLUS THERAPEUTICS, INC.Smart Summary
8-K Filing
Granted extension through November to meet Nasdaq bid price rule
Never miss a PSTV filing
Get real-time email alerts when PSTV files with the SEC.